Deepak Sampath

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

Medicine, Oncology, Pharmacology +10

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons et al. · Cancer Cell · 2009 · 831 citations · Full text

Life Sciences, Molecular Biology, Oncology +14

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Joel D. Leverson, Darren C. Phillips, Michael J. Mitten et al. · Science Translational Medicine · 2015 · 541 citations · Full text

Medicine, Oncology, Pharmacology +14

Tumour‐secreted miR‐9 promotes endothelial cell migration and angiogenesis by activating the JAK‐STAT pathway

Guanglei Zhuang, Xiumin Wu, Zhaoshi Jiang et al. · The EMBO Journal · 2012 · 472 citations · Full text

Life Sciences, Molecular Biology, Oncology +12

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

H Zhang, J Chen, Sajid Khan Tahir et al. · Cell Death and Disease · 2015 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16